European regulators initially said in July that the drug's benefits did not outweigh its risks. View on euronews ...
The EMA sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing Leqembi up for authorization in a major market.
Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback